Abstract
The first member of the next generation CoreValve "family" is the 23 mm CoreValve® Evolut™ (Medtronic, Minneapolis, MN, USA), which is indicated for an annulus range of 18 mm to 20 mm and extends the spectrum of patients with aortic stenosis that can be treated with the self-expanding CoreValve bioprosthesis. The Core-Valve Evolut provides several technical refinements and is designed to enable re-capturability in the future. Here, we report on the first case in a 93-year-old female patient who was implanted at the University Hospital Bonn, Germany, on June 1st, 2012.
MeSH terms
-
Aged, 80 and over
-
Aortic Valve Insufficiency / etiology
-
Aortic Valve Insufficiency / prevention & control
-
Aortic Valve Stenosis / physiopathology
-
Aortic Valve Stenosis / therapy*
-
Cardiac Catheterization / adverse effects
-
Cardiac Catheterization / instrumentation*
-
Evidence-Based Medicine
-
Female
-
Heart Valve Prosthesis Implantation / adverse effects
-
Heart Valve Prosthesis Implantation / instrumentation*
-
Heart Valve Prosthesis Implantation / methods
-
Heart Valve Prosthesis*
-
Hemodynamics
-
Humans
-
Patient Selection
-
Prosthesis Design
-
Risk Assessment
-
Risk Factors
-
Treatment Outcome